Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Summary

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide together with celecoxib may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well giving cyclophosphamide together with celecoxib works compared to cyclophosphamide alone in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or primary peritoneal cancer.

Timeline

Start

2003-12-22

Primary completion

2011-04-21

Completion

2019-09-13

Outcome

Missed primary endpoint

registry analysis (other test); Arm I (Cyclophosphamide Alone) vs Arm II (Cyclophosphamide + Celecoxib); p = 0.61; Log Rank NCT00538031 ↗

registry analysis (other test); Arm I (Cyclophosphamide Alone) vs Arm II (Cyclophosphamide + Celecoxib); p = 0.95; Log Rank NCT00538031 ↗

Publications

• Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Celecoxib	Other / unclassified	—	Oral
Subject	Cyclophosphamide	Other / unclassified	—	Oral

Indications